Targets › HRAS
6 programs from 5 companies in 8 trials: 7 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. (UniProt, P01112)
Open in Phaseline: the race on HRAS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Guangzhou JOYO Pharma | JYP0015 Pan-RAS inhibitor targeting the active (ON) form of wild-type and mutant RAS | KRAS, NRAS, HRAS | Phase 2 | Solid Tumor | Dec 2026 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-10203 PI3Kα:RAS breaker | PIK3CA, KRAS, NRAS, HRAS | Phase 1 | Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung Cancer | Aug 2027 |
| Adlai Nortye Biopharma | AN9025 Pan-RAS inhibitor that binds cyclophilin A (CypA) and forms a tri-complex with GTP-bound R | KRAS, NRAS, HRAS | Phase 1 | Solid Tumors (Phase 1) | Jan 2028 |
| Adlai Nortye Biopharma | AN4035 CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload | CEACAM5, KRAS, NRAS, HRAS | Phase 1 | Solid Tumor (Phase I) | Dec 2028 |
| Memorial Sloan Kettering Cancer Center | MSK-TCR5 T cell receptor (TCR) engineered to recognize RAS G12D mutations | KRAS, HRAS, NRAS | Phase 1 | Solid Tumor | Jun 2030 |
| Shanghai YingLi Pharmaceutical | YL-17231 Pan-RAS inhibitor | KRAS, HRAS, NRAS | Phase 1 | Advanced Solid Tumors | – |
Solid Tumor (2) Non-Small Cell Lung Cancer (1) Solid Tumor, Adult (1) Non-small Cell Lung Cancer (1) Solid Tumors (Phase 1) (1) Advanced Solid Tumors (1) Solid Tumor (Phase I) (1)
small molecule (4), mixed (1), protein or peptide (1)
Adlai Nortye Biopharma (2) TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1) Guangzhou JOYO Pharma (1) Shanghai YingLi Pharmaceutical (1) Memorial Sloan Kettering Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.